Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.755433
Keywords
Cabozantinib; immunogenic cell death (ICD); prostate cancer; dendritic cell (DC); TKI (tyrosine kinase inhibitors); extracellular vesicle (EV); HMGB1; immunotherapy
Categories
Ask authors/readers for more resources
Cabozantinib is a multitarget tyrosine kinase inhibitor currently used as standard therapy for medullary thyroid cancer, metastatic renal cell carcinoma, and hepatocellular carcinoma. Research suggests that Cabozantinib may exert an immunostimulatory role by inducing immunogenic stress in cancer cells and modulating dendritic cells directly.
Cabozantinib (XL-184) is a multitarget tyrosine kinase inhibitor (TKI) targeting receptor tyrosine kinases (RTKs) involved in oncogenesis and angiogenesis. It is currently the standard therapy for medullary thyroid cancer (MTC), metastatic renal cell carcinoma (mRCC), and hepatocellular carcinoma (HCC). Combination of Cabozantinib with immunotherapy is now a standard treatment in metastatic renal cancer, and its efficacy is being tested in ongoing clinical trial in prostate cancer patients. Here, we report that Cabozantinib may exert an immunostimulatory role by inducing immunogenic stress of prostate cancer cells and directly modulating dendritic cells (DCs). Cabozantinib treatment arrested the cell cycle and triggered immunogenic cell death (ICD) in prostate cancer cells in vitro. Cabozantinib had a direct effect on DCs by the down-modulation of beta-catenin and change in migratory and costimulatory phenotype of the DCs. These results may suggest possible immunomodulatory effects induced by Cabozantinib that could be exploited to optimize patient-tailored immunotherapeutic treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available